Total Payments
$542.68
2024 Payments
$38.79
Companies
8
Transactions
12
Medicare Patients
4,000
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$542.68 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $542.68 | 12 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bioventus LLC | $172.54 | 1 | $0 (2018) |
| Orthogenrx Inc. | $128.30 | 3 | $0 (2021) |
| Avanos Medical | $84.02 | 1 | $0 (2022) |
| Fidia Pharma USA Inc. | $58.88 | 3 | $0 (2024) |
| Siemens Medical Solutions USA, Inc. | $33.96 | 1 | $0 (2023) |
| Ferring Pharmaceuticals Inc. | $30.35 | 1 | $0 (2022) |
| DePuy Synthes Sales Inc. | $18.73 | 1 | $0 (2024) |
| Flexion Therapeutics, Inc. | $15.90 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38.79 | 2 | Fidia Pharma USA Inc. ($20.06) |
| 2023 | $33.96 | 1 | Siemens Medical Solutions USA, Inc. ($33.96) |
| 2022 | $133.12 | 3 | Avanos Medical ($84.02) |
| 2021 | $67.83 | 2 | Orthogenrx Inc. ($47.76) |
| 2019 | $15.90 | 1 | Flexion Therapeutics, Inc. ($15.90) |
| 2018 | $253.08 | 3 | Bioventus LLC ($172.54) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/12/2024 | Fidia Pharma USA Inc. | HYMOVIS (Device), HYALGAN, TRILURON | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: OSTEOARTHRITIS | ||||||
| 02/20/2024 | DePuy Synthes Sales Inc. | MONOVISC (Device), ORTHOVISC | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Sports Early Intervention | ||||||
| 01/13/2023 | Siemens Medical Solutions USA, Inc. | Embozene (Device) | Food and Beverage | In-kind items and services | $33.96 | General |
| Category: Oncology | ||||||
| 12/13/2022 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $30.35 | General |
| 04/05/2022 | Avanos Medical | GENVISC 850 SODIUM HYALURONATE (Device) | Food and Beverage | In-kind items and services | $84.02 | General |
| Category: PAIN MANAGEMENT | ||||||
| 02/08/2022 | Fidia Pharma USA Inc. | HYALGAN (Device) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: OSTEOARTHRITIS | ||||||
| 10/12/2021 | Orthogenrx Inc. | TriVisc sodium hyaluronate (Device), GenVisc 850 sodium hyaluronate | Food and Beverage | In-kind items and services | $47.76 | General |
| Category: Osteoarthritis | ||||||
| 04/29/2021 | Fidia Pharma USA Inc. | HYALGAN (Device) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: OSTEOARTHRITIS | ||||||
| 05/31/2019 | Flexion Therapeutics, Inc. | Zilretta (Drug) | Food and Beverage | Cash or cash equivalent | $15.90 | General |
| Category: Musculoskeletal | ||||||
| 12/14/2018 | Orthogenrx Inc. | GenVisc 850 (Device) | Food and Beverage | In-kind items and services | $30.95 | General |
| Category: Osteoarthritis | ||||||
| 07/30/2018 | Orthogenrx Inc. | GenVisc 850 (Device) | Food and Beverage | In-kind items and services | $49.59 | General |
| Category: Osteoarthritis | ||||||
| 07/26/2018 | Bioventus LLC | GELSYN 3 (Device) | Food and Beverage | In-kind items and services | $172.54 | General |
| Category: Not Applicable | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,343 | 34,760 | $755,427 | $252,850 |
| 2022 | 10 | 1,583 | 21,669 | $564,741 | $223,891 |
| 2021 | 6 | 1,074 | 86,508 | $1.2M | $580,913 |
Total Patients
4,000
Total Services
142,937
Medicare Billing
$1.1M
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | Office | 2023 | 192 | 17,200 | $378,368 | $99,781 | 26.4% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2023 | 248 | 754 | $156,890 | $68,269 | 43.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 249 | 767 | $113,532 | $43,210 | 38.1% |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | Office | 2023 | 205 | 10,736 | $21,028 | $11,739 | 55.8% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2023 | 22 | 832 | $30,739 | $10,894 | 35.4% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 104 | 165 | $19,282 | $7,558 | 39.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 44 | 71 | $8,798 | $3,449 | 39.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 56 | 56 | $8,211 | $2,536 | 30.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 41 | 41 | $3,866 | $1,503 | 38.9% |
| 73580 | Review by radiologist of knee joint image | Office | 2023 | 13 | 13 | $4,101 | $1,324 | 32.3% |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | Office | 2023 | 38 | 3,900 | $3,458 | $1,310 | 37.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 34 | 34 | $3,753 | $1,203 | 32.1% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 97 | 191 | $3,404 | $74.89 | 2.2% |
| J7329 | Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg | Office | 2022 | 128 | 6,778 | $180,430 | $67,767 | 37.6% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2022 | 368 | 655 | $134,505 | $62,995 | 46.8% |
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | Office | 2022 | 133 | 4,800 | $111,550 | $38,188 | 34.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 368 | 657 | $80,614 | $34,596 | 42.9% |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | Office | 2022 | 358 | 8,143 | $14,332 | $5,118 | 35.7% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2022 | 11 | 352 | $13,292 | $4,678 | 35.2% |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 2022 | 18 | 75 | $12,428 | $4,432 | 35.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 78 | 78 | $11,512 | $3,933 | 34.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 51 | 51 | $4,479 | $2,146 | 47.9% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 70 | 80 | $1,600 | $39.07 | 2.4% |
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | Office | 2021 | 228 | 28,178 | $682,892 | $378,001 | 55.4% |
| 77002 | Fluoroscopic guidance for insertion of needle | Office | 2021 | 233 | 1,137 | $232,864 | $99,271 | 42.6% |
About Dr. John Rush, MD
Dr. John Rush, MD is a Emergency Medicine healthcare provider based in Spring, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851337281.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Rush, MD has received a total of $542.68 in payments from pharmaceutical and medical device companies, with $38.79 received in 2024. These payments were reported across 12 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($542.68).
As a Medicare-enrolled provider, Rush has provided services to 4,000 Medicare beneficiaries, totaling 142,937 services with total Medicare billing of $1.1M. Data is available for 3 years (2021–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Location Spring, TX
- Active Since 06/22/2006
- Last Updated 07/21/2022
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1851337281
Products in Payments
- GELSYN 3 (Device) $172.54
- GENVISC 850 SODIUM HYALURONATE (Device) $84.02
- GenVisc 850 (Device) $80.54
- TriVisc sodium hyaluronate (Device) $47.76
- HYALGAN (Device) $38.82
- Embozene (Device) $33.96
- HYMOVIS (Device) $20.06
- MONOVISC (Device) $18.73
- Zilretta (Drug) $15.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Spring
Rajeev Pethe, M.d, M.D
Emergency Medicine — Payments: $825.58
Emergency Medicine $825.58
Naim El-Aswad, Md, MD
Emergency Medicine — Payments: $98.72
Emergency Medicine $98.72
Amina Shaikh, M.d, M.D
Emergency Medicine — Payments: $83.81
Emergency Medicine $83.81
James Rinkle, M.d, M.D
Emergency Medicine — Payments: $25.94
Emergency Medicine $25.94
Dr. Ismail Adesanya, M.d, M.D
Emergency Medicine — Payments: $22.75
Emergency Medicine $22.75
Dr. Howard Hood, Md, MD
Emergency Medicine
Emergency Medicine